Return to Special Authority drug list
Generic name |
upadacitinib |
|
Strength & form |
15 mg, 30 mg, 45 mg extended-release tablets |
Special Authority criteria |
Approval period |
---|---|
InitialModerately to severely active Crohn's disease For the treatment of adult patients with moderately to severely active Crohn's disease when ALL of the following criteria are met:
AND
AND
Fistulizing Crohn's disease For the treatment of adult patients with active fistulizing Crohn's disease when ALL of the following criteria are met:
AND
|
16 weeks |
RenewalModerately to severely active Crohn’s disease For the continued treatment of adult patients with moderately to severely active Crohn's disease when ALL of the following criteria are met:
AND
Fistulizing Crohn's disease For the continued treatment of adult patients with active fistulizing Crohn's disease when ALL of the following criteria are met:
AND
|